Trial Profile
Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms POMOSCH
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 10 Jan 2012 Actual patient number (790) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned end date changed from Mar 2011 to Sep 2011 as reported by ClinicalTrials.gov.